PLEASE CALL US FOR AN APPOINTMENT
Chelation: Treating Heavy Metal Toxicity and Cardiovascular Disease
The term chelation (pronounced key-lay-shun) is derived from “chelos”, the Greek word for claw. Chelation therapy is an established complementary and alternative medicine elective aimed at restoring whole body health and reducing body burden of heavy metals, such as lead and mercury from the body. Chelation therapy is also used in the treatment of cardiovascular, autoimmune and neurodegenerative diseases. Please CLICK HERE for a list of conditions treated using chelation therapy.
Heavy metals such as lead, mercury and arsenic are toxic to the body. High levels of these toxic metals in the body often result in a wide range of debilitating symptoms. Lead toxicity can lead to higher rates of Parkinsonism and cognitive decline in adults, and learning and behavioral difficulties in children. Mercury exposure is associated with mood disturbances, cardiovascular conditions such as high blood pressure, infertility and immune dysfunction. Arsenic is a known carcinogen and can increase the risk for diabetes.
At Anatara Medicine, Our Team of practitioners uses the most accurate laboratory assessment to evaluate heavy metal toxicity. This will be done by utilizing symptom questionnaires, physical examinations and laboratory testing such as blood and urine.
A number of different chelating agents are used in chelation therapy. Your doctor will choose the appropriate one depending on the mineral or heavy metal to be chelated. For example, DMPS is commonly used in treating mercury toxicity and EDTA is used in treating atherosclerosis. In addition to using pharmaceutical chelating agents we also include natural agents, such as dietary fiber, cilantro, chlorella, etc., to be taken during your treatment for increased chelation and detoxification support.
Please CLICK HERE for Frequently Asked Questions (FAQs).
Chelation therapy has also been studied as a therapy for cardiovascular disease. TACT (Trial to Assess Chelation Therapy) is the first large scale study to determine the efficacy and safety of chelation therapy, with or without high-dose vitamins, for those with cardiovascular disease including prior heart attacks, coronary artery disease, diabetes, etc. The preliminary results of this 10 year, $31 million study showed that EDTA chelation therapy produced statistically significant reductions in cardiovascular events. Patients with diabetes were more positively impacted showing a 40% reduction in risk of death from heart disease, 52% reduction in recurrent heart attacks and 43% reduction in death from any cause. Gervasio Lamas, M.D., the study’s principal investigator, remarked “These are striking results that, if supported by future research, could point the way towards new treatments to prevent complications of diabetes.”
Research studies investigating the implications of chelation therapy on autism, neurodegenerative diseases such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, macular degeneration, rheumatoid arthritis and others have been published. The FDA has approved 11 chelating agents, including EDTA and DMS to treat heavy metal toxicities. Currently, chelation therapy is not approved by the FDA to treat specific conditions other than reducing heavy metal burden.